Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Retained Earnings: 2010-2025

Historic Retained Earnings for Cytokinetics (CYTK) over the last 13 years, with Sep 2025 value amounting to -$3.3 billion.

  • Cytokinetics' Retained Earnings fell 27.06% to -$3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 billion, marking a year-over-year decrease of 27.06%. This contributed to the annual value of -$2.7 billion for FY2024, which is 27.91% down from last year.
  • As of Q3 2025, Cytokinetics' Retained Earnings stood at -$3.3 billion, which was down 10.12% from -$3.0 billion recorded in Q2 2025.
  • Cytokinetics' Retained Earnings' 5-year high stood at -$1.0 billion during Q1 2021, with a 5-year trough of -$3.3 billion in Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$2.4 billion (2024), whereas its average is -$2.4 billion.
  • Data for Cytokinetics' Retained Earnings shows a maximum YoY tumbled of 41.31% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Retained Earnings stood at -$1.2 billion in 2021, then slumped by 31.33% to -$1.6 billion in 2022, then slumped by 33.18% to -$2.1 billion in 2023, then fell by 27.91% to -$2.7 billion in 2024, then dropped by 27.06% to -$3.3 billion in 2025.
  • Its last three reported values are -$3.3 billion in Q3 2025, -$3.0 billion for Q2 2025, and -$2.9 billion during Q1 2025.